Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation Via Protease Activated Receptor-1.

Petzold T, Thienel M, Dannenberg LK, Mourikis P, Helten C, Ayhan A, M'Pembele R, Achilles A, Trojovsky K, Konsek D, Zang Z, Regenauer R, Pircher J, Ehrlich A, Lüsebrink E, Nicolai L, Stocker T, Brandl R, Röschentaler F, Strecker J, Saleh I, Spannagl M, Mayr CH, Schiller HB, Jung C, Gerdes N, Hoffmann T, Levkau B, Hohlfeld T, Zeus T, Schulz C, Kelm M, Polzin A.

Circ Res. 2019 Dec 20. doi: 10.1161/CIRCRESAHA.119.315099. [Epub ahead of print]

PMID:
31859592
2.

Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.

Petzold T, Thienel M, Konrad I, Schubert I, Regenauer R, Hoppe B, Lorenz M, Eckart A, Chandraratne S, Lennerz C, Kolb C, Braun D, Jamasbi J, Brandl R, Braun S, Siess W, Schulz C, Massberg S.

Sci Transl Med. 2016 Nov 30;8(367):367ra168.

PMID:
27903864

Supplemental Content

Loading ...
Support Center